Seza Ozen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3539650/publications.pdf

Version: 2024-02-01

148 papers	6,557 citations	109311 35 h-index	74160 75 g-index
153 all docs	153 docs citations	153 times ranked	6245 citing authors

#	Article	IF	Citations
1	Response to: â€˜Correspondence on â€˜Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trialâ€™â€™ by Satiset al. Annals of the Rheumatic Diseases, 2022, 81, e257-e257.	0.9	0
2	Comparison of IVIG resistance predictive models in Kawasaki disease. Pediatric Research, 2022, 91, 621-626.	2.3	16
3	IgG4-related disease in pediatric patients: a single-center experience. Rheumatology International, 2022, 42, 1177-1185.	3.0	10
4	Spinal involvement in juvenile idiopathic arthritis: what do we miss without imaging?. Rheumatology International, 2022, 42, 519-527.	3.0	6
5	Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study. Rheumatology International, 2022, 42, 879-889.	3.0	35
6	The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study. Rheumatology International, 2022, 42, 469-475.	3.0	16
7	Impact of the COVID-19 pandemic on the frequency of the pediatric rheumatic diseases. Rheumatology International, 2022, 42, 51-57.	3.0	13
8	Challenges in diagnosing COVID-19 related disease in pediatric patients with rheumatic disease. Modern Rheumatology, 2022, 32, 1108-1113.	1.8	4
9	The performances of the ILAR, ASAS, and PRINTO classification criteria in ERA patients: a comparison study. Clinical Rheumatology, 2022, 41, 1785-1792.	2.2	5
10	Polyarteritis nodosa. Current Opinion in Pediatrics, 2022, 34, 229-233.	2.0	4
11	Probiotic use in the prophylaxis of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: a retrospective cohort study. Rheumatology International, 2022, , 1.	3.0	7
12	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Annals of the Rheumatic Diseases, 2022, 81, 601-613.	0.9	31
13	The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort. Seminars in Arthritis and Rheumatism, 2022, 52, 151957.	3.4	7
14	Early is superior to late plasma exchange for severe <scp>multisystem inflammatory syndrome in children</scp>. Journal of Clinical Apheresis, 2022, , .	1.3	3
15	The difference of the inflammatory milieu in MIS-C and severe COVID-19. Pediatric Research, 2022, 92, 1805-1814.	2.3	24
16	Treatment of childhood-onset Takayasu arteritis: switching between anti-TNF and anti-IL-6 agents. Rheumatology, 2022, 61, 4885-4891.	1.9	4
17	Biologics for immunoglobulin A vasculitis: targeting vasculitis or comorbid disease?. Internal and Emergency Medicine, 2022, 17, 1599-1608.	2.0	2
18	FC040: Kidney Transplantation in Childhood-Onset ANCA-Associated Vasculitis: Outcomes in a Multicentre Cohort. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0

#	Article	IF	Citations
19	Neutrophil-to-Lymphocyte Ratio: An Easy Marker for the Diagnosis and Monitoring of Inflammatory Bowel Disease in Children. Digestive Diseases and Sciences, 2022, , .	2.3	5
20	Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal Î±-toxin. Science, 2022, 376, eabm6380.	12.6	25
21	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the Rheumatic Diseases, 2022, 81, 907-921.	0.9	38
22	The challenges in diagnosing pediatric primary antiphospholipid syndrome. Lupus, 2022, 31, 1269-1275.	1.6	4
23	COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis. Seminars in Arthritis and Rheumatism, 2022, 55, 152047.	3.4	24
24	Pulmonary Manifestations of Systemic Vasculitis in Children. Pediatric Clinics of North America, 2021, 68, 167-176.	1.8	4
25	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology, 2021, 60, 3799-3808.	1.9	29
26	Inflammatory milieu of muscle biopsies in juvenile dermatomyositis. Rheumatology International, 2021, 41, 77-85.	3.0	8
27	Multisystem inflammatory syndrome in children during the COVID-19 pandemic in Turkey: first report from the Eastern Mediterranean. Clinical Rheumatology, 2021, 40, 3227-3237.	2.2	29
28	Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. Seminars in Arthritis and Rheumatism, 2021, 51, 95-100.	3.4	11
29	Plasma checkpoint protein levels and galectin-9 in juvenile systemic lupus erythematosus. Lupus, 2021, 30, 998-1004.	1.6	3
30	Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature Reviews Rheumatology, 2021, 17, 257-269.	8.0	52
31	Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?. Pediatric Nephrology, 2021, 36, 3771-3776.	1.7	12
32	Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes. Pediatric Research, 2021, 90, 744-751.	2.3	6
33	Next Generation Sequencing Based Multiplex Long-Range PCR for Routine Genotyping of Autoinflammatory Disorders. Frontiers in Immunology, 2021, 12, 666273.	4.8	2
34	Systematic review of childhood-onset polyarteritis nodosa and DADA2. Seminars in Arthritis and Rheumatism, 2021, 51, 559-564.	3.4	14
35	Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. Journal of Clinical Immunology, 2021, 41, 1633-1647.	3.8	43
36	Real-world data on MTX tolerance with regimens used in children versus adults. Clinical Rheumatology, 2021, 40, 5095-5102.	2.2	2

#	Article	IF	Citations
37	Update in familial Mediterranean fever. Current Opinion in Rheumatology, 2021, 33, 398-402.	4.3	16
38	Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell death. Cell, 2021, 184, 4447-4463.e20.	28.9	64
39	The role of vascular inflammation markers in deficiency of adenosine deaminase 2. Seminars in Arthritis and Rheumatism, 2021, 51, 839-844.	3.4	7
40	Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group. Seminars in Arthritis and Rheumatism, 2021, 51, 957-961.	3.4	7
41	Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER. Pediatric Rheumatology, 2021, 19, 134.	2.1	15
42	Clinical spectrum of children with interstitial pneumonia with autoimmune features. Respiratory Medicine, 2021, 187, 106566.	2.9	3
43	Familial Mediterranean fever-related miR-197-3p targets IL1R1 gene and modulates inflammation in monocytes and synovial fibroblasts. Scientific Reports, 2021, 11, 685.	3.3	28
44	Whole exome sequencing in unclassified autoinflammatory diseases: more monogenic diseases in the pipeline?. Rheumatology, 2021, 60, 607-616.	1.9	13
45	Deubiquitination of proteasome subunits by OTULIN regulates type I IFN production. Science Advances, 2021, 7, eabi6794.	10.3	8
46	Is Takayasu's arteritis more severe in children?. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 32-38.	0.8	3
47	Validation of the EULAR/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients. Clinical and Experimental Rheumatology, 2021, 39, 688-694.	0.8	2
48	Is Takayasu's arteritis more severe in children?. Clinical and Experimental Rheumatology, 2021, 39, 32-38.	0.8	16
49	Validation of the EULAR/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients. Clinical and Experimental Rheumatology, 2021, 39, 688-694.	0.8	2
50	A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2. Journal of Rheumatology, 2020, 47, 117-125.	2.0	65
51	Rheumatological manifestations in inborn errors of immunity. Pediatric Research, 2020, 87, 293-299.	2.3	3
52	Performance of the new â€˜Eurofever/PRINTO classification criteriaâ€™ in FMF patients. Seminars in Arthritis and Rheumatism, 2020, 50, 172-175.	3.4	15
53	A rare cause of steroid-resistant nephrotic syndrome in a child: Answers. Pediatric Nephrology, 2020, 35, 621-623.	1.7	0
54	A rare cause of steroid resistant nephrotic syndrome in a child: Questions. Pediatric Nephrology, 2020, 35, 619-620.	1.7	0

#	Article	IF	Citations
55	Kawasaki-like disease in children with COVID-19. Rheumatology International, 2020, 40, 2105-2115.	3.0	67
56	Response to letter to the editor. Seminars in Arthritis and Rheumatism, 2020, 50, 1553.	3.4	0
57	Implications of COVID-19 in pediatric rheumatology. Rheumatology International, 2020, 40, 1193-1213.	3.0	35
58	ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era. Clinical Chemistry, 2020, 66, 525-536.	3.2	43
59	Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Annals of the Rheumatic Diseases, 2020, 79, 1362-1369.	0.9	39
60	Childhood vasculitis. Rheumatology, 2020, 59, iii95-iii100.	1.9	18
61	Measuring Vasculitis with Numbers: Outcome Scores. Current Rheumatology Reviews, 2020, 16, 21-28.	0.8	6
62	ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy. Human Mutation, 2020, 41, 1469-1487.	2.5	8
63	Burden of illness in hereditary periodic fevers: a multinational observational patient diary study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 26-34.	0.8	3
64	The Challenge of Treating Pulmonary Vasculitis in BehÃ§et Disease: Two Pediatric Cases. Pediatrics, 2019, 144, .	2.1	9
65	The European network for care of children with paediatric rheumatic diseases: care across borders. Rheumatology, 2019, 58, 1188-1195.	1.9	15
66	EPIC-TABSAT: analysis tool for targeted bisulfite sequencing experiments and array-based methylation studies. Nucleic Acids Research, 2019, 47, W166-W170.	14.5	19
67	The factors affecting the disease course in Kawasaki disease. Rheumatology International, 2019, 39, 1343-1349.	3.0	11
68	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
69	Different histological classifications for Henoch-SchÃ¶nlein purpura nephritis: which one should be used?. Pediatric Rheumatology, 2019, 17, 10.	2.1	50
70	AB1041â€…PREVALENCE OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) SUBGROUPS AND JIA-ASSOCIATED UVEITIS AMONG JIA PATIENTS ADMITTED TO REFERRAL PEDIATRIC RHEUMATOLOGY CLINICS IN TURKEY: A RETROSPECTIVE STUDY, JUPITER. , 2019, , .		0
71	OP0152â€…OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DOES NOT SHOW SIGNS OF T-CELL EXHAUSTION, IN SPITE OF INCREASED EXPRESSION OF CO-INHIBITORY RECEPTORS. , 2019, , .		0
72	Whatâ€™s new in autoinflammation?. Pediatric Nephrology, 2019, 34, 2449-2456.	1.7	8

#	Article	IF	Citations
73	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptorâ€“associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
74	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides â€“ the SHARE initiative. Rheumatology, 2019, 58, 656-671.	1.9	77
75	European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease â€“ the SHARE initiative. Rheumatology, 2019, 58, 672-682.	1.9	103
76	Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. Multiple Sclerosis and Related Disorders, 2019, 27, 20-22.	2.0	4
77	Polyarteritis nodosa: lessons from 25 years of experience. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 52-56.	0.8	9
78	The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 395-402.	3.0	4
79	Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clinical Rheumatology, 2018, 37, 3329-3335.	2.2	97
80	A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Annals of the Rheumatic Diseases, 2018, 77, 728-735.	0.9	176
81	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Annals of the Rheumatic Diseases, 2018, 77, 319-327.	0.9	9
82	Update on the epidemiology and disease outcome of Familial Mediterranean fever. Best Practice and Research in Clinical Rheumatology, 2018, 32, 254-260.	3.3	23
83	Towards a new set of classification criteria for PFAPA syndrome. Pediatric Rheumatology, 2018, 16, 60.	2.1	32
84	Pediatric forms of vasculitis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 137-147.	3.3	11
85	Pediatric Nephrology and Rheumatology Practice Patterns in Granulomatosis with Polyangiitis: A Midwest Pediatric Nephrology Consortium Study. International Journal of Nephrology, 2018, 2018, 1-9.	1.3	1
86	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27
87	Whole Exome Sequencing in Early-onset Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 1671-1679.	2.0	37
88	A retrospective study comparing the phenotype and outcomes of patients with polyarteritis nodosa between UK and Turkish cohorts. Rheumatology International, 2018, 38, 1833-1840.	3.0	18
89	Vasculitis Pathogenesis: Can We Talk About Precision Medicine?. Frontiers in Immunology, 2018, 9, 1892.	4.8	18
90	Potential role of pyrin, the protein mutated in familial Mediterranean fever, during inflammatory cell migration. Clinical and Experimental Rheumatology, 2018, 36, 116-124.	0.8	9

#	Article	IF	Citations
91	Assessment of autonomic functions in children with familial Mediterranean fever by using heart rate variability measurements. International Journal of Rheumatic Diseases, 2017, 20, 2086-2092.	1.9	8
92	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
93	The changing face of polyarteritis nodosa and necrotizing vasculitis. Nature Reviews Rheumatology, 2017, 13, 381-386.	8.0	77
94	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1788-1796.	0.9	139
95	Comparing polyarteritis nodosa in children and adults: a single center study. International Journal of Rheumatic Diseases, 2017, 20, 1016-1022.	1.9	30
96	IgA vasculitis (Henochâ€“SchÃ¶nlein purpura) in children. Expert Opinion on Orphan Drugs, 2017, 5, 405-410.	0.8	1
97	A clinical update on inflammasomopathies. International Immunology, 2017, 29, 393-400.	4.0	20
98	IgA vasculitis (Henochâ€“SchÃ¶nlein): Case definition andguidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine, 2017, 35, 1559-1566.	3.8	9
99	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Annals of the Rheumatic Diseases, 2017, 76, 906-913.	0.9	123
100	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1965-1973.	0.9	105
101	Autoinflammatory Diseases with Periodic Fevers. Current Rheumatology Reports, 2017, 19, 41.	4.7	66
102	Childhood systemic vasculitis. Best Practice and Research in Clinical Rheumatology, 2017, 31, 558-575.	3.3	18
103	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases, 2017, 12, 167.	2.7	52
104	Recent advances in childhood vasculitis. Current Opinion in Rheumatology, 2017, 29, 530-534.	4.3	8
105	Final diagnosis of children and adolescents with musculoskeletal complaints. Minerva Pediatrics, 2017, 69, 50-58.	0.4	4
106	Comparison of patients with familial Mediterranean fever accompanied with sacroiliitis and patients with juvenile spondyloarthropathy. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 124-127.	0.8	7
107	Alteration of the microRNA expression profile in familial Mediterranean fever patients. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 90-94.	0.8	13
108	Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10127-10132.	7.1	206

#	Article	IF	Citations
109	Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nature Genetics, 2016, 48, 67-73.	21.4	513
110	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.9	338
111	EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2016, 75, 644-651.	0.9	393
112	What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review. Rheumatology International, 2016, 36, 483-487.	3.0	33
113	Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review. Rheumatology International, 2016, 36, 325-331.	3.0	32
114	Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. Journal of the American Academy of Dermatology, 2016, 74, 186-189.	1.2	64
115	Vasculitis as an adverse event following immunization â€“ Systematic literature review. Vaccine, 2016, 34, 6641-6651.	3.8	87
116	Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Vaccine, 2016, 34, 6634-6640.	3.8	41
117	Vasculitis in children. Nephrology Dialysis Transplantation, 2015, 30 Suppl 1, i94-103.	0.7	24
118	HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	7.1	139
119	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.9	215
120	Vasculitis: do we know more to classify better?. Pediatric Nephrology, 2015, 30, 1425-1432.	1.7	8
121	Etanercept treatment in five cases of refractory chronic recurrent multifocal osteomyelitis (CRMO). Joint Bone Spine, 2015, 82, 471-473.	1.6	16
122	A field on the move. Nature Reviews Rheumatology, 2015, 11, 625-626.	8.0	0
123	Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children. Clinical and Experimental Rheumatology, 2015, 33, S156-62.	0.8	6
124	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. Arthritis and Rheumatology, 2014, 66, 3160-3169.	5.6	322
125	Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Annals of the Rheumatic Diseases, 2014, 73, 662-667.	0.9	92
126	Response to: â€˜The country of residence affects the phenotype of familial Mediterranean fever? Is it real or a selection bias?â€™ by Korkmaz. Annals of the Rheumatic Diseases, 2014, 73, e53-e53.	0.9	0

#	Article	IF	Citations
127	In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes. Journal of Biomaterials Applications, 2014, 29, 524-542.	2.4	17
128	Endothelial function in patients with familial Mediterranean fever-related amyloidosis and association with cardiovascular events. Rheumatology, 2014, 53, 2002-2008.	1.9	21
129	The invisible part of the iceberg: qualitative aspects of childhood vasculitis. Clinical and Experimental Rheumatology, 2014, 32, S122-7.	0.8	4
130	Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Annals of the Rheumatic Diseases, 2013, 72, 1628-1633.	0.9	123
131	Pediatric Vasculitis. Current Rheumatology Reports, 2012, 14, 121-129.	4.7	30
132	Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. Clinical and Experimental Rheumatology, 2012, 30, S162-8.	0.8	13
133	The Eurofever Project: towards better care for autoinflammatory diseases. European Journal of Pediatrics, 2011, 170, 445-452.	2.7	41
134	The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clinical and Experimental Rheumatology, 2011, 29, 111-6.	0.8	35
135	Pediatric onset BehÃ§et disease. Current Opinion in Rheumatology, 2010, 22, 585-589.	4.3	23
136	The â€œotherâ€•vasculitis syndromes and kidney involvement. Pediatric Nephrology, 2010, 25, 1633-1639.	1.7	21
137	Update in paediatric vasculitis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 679-688.	3.3	9
138	Childhood vasculitides in Turkey: a nationwide survey. Clinical Rheumatology, 2006, 26, 196-200.	2.2	88
139	Arg753Gln TLR-2 polymorphism in familial mediterranean fever: linking the environment to the phenotype in a monogenic inflammatory disease. Journal of Rheumatology, 2006, 33, 2498-500.	2.0	26
140	Problems in classifying vasculitis in children. Pediatric Nephrology, 2005, 20, 1214-1218.	1.7	20
141	Renal amyloidosis in familial Mediterranean fever. Kidney International, 2004, 65, 1118-1127.	5.2	34
142	Juvenile polyarteritis: Results of a multicenter survey of 110 children. Journal of Pediatrics, 2004, 145, 517-522.	1.8	196
143	Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation?. Journal of Rheumatology, 2003, 30, 2014-8.	2.0	87
144	Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. European Journal of Human Genetics, 2001, 9, 553-555.	2.8	273

#	Article	IF	Citations
145	MEFV mutations in Behï¿½et's disease. Human Mutation, 2000, 16, 271-272.	2.5	144
146	Enalaprilâ€induced anemia in a renal transplant patient. Pediatrics International, 1997, 39, 626-627.	0.5	3
147	Journey of Vasculitis at Hacettepe University: from the Establishment of University to the Hacettepe AAV Workshop, 2020. Acta Medica, 0, 52, 4-6.	0.2	1
148	The performance of IgG4-related disease responder index in children. Clinical and Experimental Rheumatology, 0, , .	0.8	0